minims fluorescein sodium 1% silmatilgad, lahus
laboratoire chauvin s.a. - fluorestseiin - silmatilgad, lahus - 10mg 1ml 0.5ml 20tk
heparine sodium sterop süstelahus
sterop overseas s.a. laboratories - naatriumhepariin - süstelahus - 5000rÜ 1ml 5ml 10tk
heparin sodium panpharma süstelahus
panpharma laboratories - naatriumhepariin - süstelahus - 5000rÜ 1ml 5ml 10tk
heparin sodium rovi süstelahus
laboratorios farmaceuticos rovi s.a. - naatriumhepariin - süstelahus - 5000tÜ 1ml 5ml 100tk
molaxole suukaudse lahuse pulber
meda pharma sia - makrogool+naatriumkloriid+naatriumvesinikkarbonaat+kaaliumkloriid - suukaudse lahuse pulber - 13,125mg+350,7mg+178,5mg+46,6mg 30tk; 13,125mg+350,7mg+178,5mg+46,6mg 20tk; 13,125mg+350,7mg+178,5mg+46,6mg 2tk; 13,125mg+350,7mg+178,5mg+46,6mg 8tk; 13,125mg+350,7mg+178,5mg+46,6mg 6tk; 13,125mg+350,7mg+178,5mg+46,6mg 60tk; 13,125mg+350,7mg+178,5mg+46,6mg 100tk; 13,125mg+350,7mg+178,5mg+46,6mg 10tk
vistaprep suukaudse lahuse pulber
tillotts pharma ab - makrogool+naatriumkloriid+naatriumvesinikkarbonaat+kaaliumkloriid - suukaudse lahuse pulber - 105g+2,8g+1,43g+0,37g 4tk
fortrans suukaudse lahuse pulber
ipsen consumer healthcare s.a.s. - naatriumsulfaat, veevaba+kaaliumkloriid+naatriumkloriid+makrogool+naatriumvesinikkarbonaat - suukaudse lahuse pulber - 5,7g+0,75g+1,46g+64g+1,68g 4tk
lecicarbon e co2-laxans rektaalsuposiit
haupt pharma wolfratshausen gmbh - naatriumvesinikkarbonaat+naatriumdivesinikfosfaat - rektaalsuposiit - 500mg+680mg 10tk
pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.